Supplemental Data Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins
By Dohoon Kim, Chun-Hyung Kim, J. Moon, Y. Chung, M. Chang, B. Han, Sanghyeok Ko, Eungi Yang, K. Y. Cha, Robert Lanza and 1 more. 2009
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- M. Stadtfeld
- K. Hochedlinger
- S. Yamanaka
- S. L. Ginn
- Kathrin Plath
- Luigi A. Warren
- Esther Y. Son
- H. Ban
Citations in the corpus
- Gene therapy clinical trials worldwide to 2012 – an update (2013, background): “Originally produced by retroviral-mediated delivery, refinements to the system using non-integrating vectors and transient expression systems [77–81] will also address safety”
- Reprogramming of mouse and human cells to pluripotency using mature microRNAs. (2011, background): “Reprogramming using just protein or mRNA has also been reported, but the protocols involved are technically challenging (Kim et al., 2009; Zhou et al., 2009; Warren et al., 2010).”
- Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. (2010, methodology): “The original study described trisomy in chromosomes 1 and 9 in p-hiPS01 and p-hiPS02 as well as in the parental somatic cell line (Kim et al., 2009).”
- Gene therapy clinical trials worldwide to 2017: An update (2018, background): “For example, the use of non‐integrating vectors, transient expression systems and small molecules to deliver transcription factors to induced pluripotent stem (iPS) cells are addressing safety concerns by eliminating unwanted long‐term expression of the encoded transcription factors and the possibil”
- Induced pluripotency: history, mechanisms, and applications. (2010, background): “Consistent with this notion, somatic cells that express other reprogramming factors endogenously do not require administration of the corresponding exogenous factor(s), as has been demonstrated for neural stem cells that can be converted into iPSCs by Oct4 alone (Table 2; JB Kim et al. 2009a).”
- A Small Molecule Inhibitor of Tgf-β Signaling Replaces Sox2 in Reprogramming by Inducing Nanog (2009, background): “Identification of such compounds would allow reprogramming that would not be impeded by the laborious nature of protein transduction or the safety concerns surrounding transgenic approaches (Kaji et al., 2009; Kim et al., 2009; Okita et al., 2008).”